Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Tuberculosis Trials Consortium (TBTC)						Print
																Related Pages
										**On This Page**
			About TBTCTBTC ActivitiesTBTC Clinical SitesTBTC PartnersRoles in TBTCAbout TBTCTBTC: Tuberculosis Trials Consortium
CDC assesses the need for and conducts studies of new or existing drugs and regimens used in the prevention and treatment of TB, including dosage, duration, pharmacokinetics, and toxicity.  Currently, most of these trials and studies are conducted by the Tuberculosis Trials Consortium (TBTC), a unique collaboration of researchers from CDC, domestic and international public health departments and academic medical centers, and selected Veterans Administration medical centers. TBTC’s mission is to conduct programmatically relevant research concerning the diagnosis, clinical management, and prevention of tuberculosis infection and disease.
The work of TBTC:
expands clinical and epidemiologic knowledge of TB,
integrates research into the care of persons with TB infection and disease,
promotes research within local TB programs through collaboration on clinical research of relevance to public health settings, and
provides a forum for international collaborative research of importance to both domestic and international TB control.Since its inception, TBTC clinical trials have had significant impact on TB treatment and prevention:
U.S. Public Health Service Study 22 substantially influenced American Thoracic Society (ATS)/CDC/Infectious Disease Society of America (IDSA) guidelines for treatment of TB disease. TBTC Study 34 influenced the 2017 ATS/CDC/IDSA guidelines for TB diagnosis, and TBTC Studies 26 and 33 led to updates in National Tuberculosis Controllers Association/CDC guidelines for treatment of latent TB infection.
TBTC Study 31/ACTG A5349 was the first trial to achieve success with a 4-month treatment regimen for active TB; it demonstrated that a four-month daily treatment regimen containing a combination of high-dose rifapentine and moxifloxacin is non-inferior to the standard six-month daily regimen for drug-susceptible TB disease. The results of this study will inform future TB disease treatment guidelines and will guide future treatment-shortening trials.
TBTC Study 23 results have led to modification of CDC’s recommendations for treatment of TB and HIV.TBTC ActivitiesThe current pipeline of new and re-purposed anti-TB drug candidates is the most promising in 40 years.  Advances in TB clinical trials science have fostered the progress of these agents, supported by many members of the global TB control community. With commitment and support from CDC, the TBTC adds importantly to the resources available for these clinical trials and is expected to continue to make useful contributions to TB treatment, prevention, and control.
Activities of TBTC include:
**TBTC Study 31**: this large trial of a 4-month rifapentine-based regimen for treatment of drug-sensitive TB, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, AIDS Clinical Trials Group (as ACTG A5349), demonstrated non-inferiority of one of two test regimens. The trial has concluded, and many analytic activities are currently underway. *ClinicalTrials.gov Identifier: NCT02410772*
**TBTC Study 35**: this is a Phase I/2 open-label, single arm, exposure-controlled study to determine appropriate dosing of a novel water-dispersible, child-friendly formulation of rifapentine with isoniazid in children aged 0-12 years. The trial aims also to assess safety of this formulation in HIV-infected and HIV-uninfected children. If successful, the trial will contribute to global availability of a pediatric formulation that can be used to treat latent TB infection in young children. *ClinicalTrials.gov Identifier: NCT03730181*
**TBTC Study 37**: this is an open label, multi-center, phase 3 randomized controlled non-inferiority trial that compares the safety and effectiveness of a 6-week regimen of daily rifapentine against the current standard of 12-16 weeks of rifamycin-based treatment for latent TB infection.  *ClinicalTrials.gov Identifier: NCT03474029*
**CRUSH-TB**: this phase 2C trial aims to assess the efficacy and safety of several regimens based on novel agents in the treatment of drug-sensitive TB disease. The trial is well-advanced in planning.TBTC Clinical SitesTBTC sites are funded in one of two ways, either through individual contracts with CDC or as part of a sub-network coordinated by investigators at the Washington, D.C. Veterans Affairs (VA) Medical Center.  Every 10 years, both sides of the consortium undergo re-competition. In March 2021, CDC announced the sites for the research cycle through December 2030.
As in prior years, the TBTC re-competition resulted in awards to new as well as previous clinical sites. The members of TBTC combine outstanding scientific expertise and demonstrated TB trials capacity. As in the past, some of these awards reflect collaborations involving North American and other international institutions.
TBTC sites are located in Australia, Benin, Canada, Haiti, South Africa, Uganda, the United States, and Vietnam.TBTC Map [PDF – 464 KB]
The map shows affiliation of international and domestic sites with universities, medical centers, and U.S. Department of Veterans Affairs (VA) locations.TBTC PartnersDeveloping new TB treatment and prevention strategies depends upon collaboration among academics, private sector and government researchers, public health departments, manufacturers of pharmaceuticals, regulatory agencies, and non-governmental organizations. CDC works closely with such organizations as:
the U.S. Food and Drug Administration,
the National Institutes of Health and its National Institute of Allergy and Infectious Diseases,
the Global Alliance for TB Drug Development, and
others within and outside the United States.Such partnerships build upon the long tradition of collaboration in pursuit of important public health goals.Roles in TBTC**CDC**
The CDC oversees, and collaborates in, the work of TBTC.  The TBTC CDC team is composed of medical officers, epidemiologists, trialists, health scientists, microbiologists, data analysts, data managers, programmers, data clerks, multiple public health students, administrative support staff, and others. The CDC team supports the TBTC by:
functioning as the TBTC’s Data and Coordinating Center;
participating in protocol development;
guiding implementation, analysis, and interpretation of each trial;
conducting the central monitoring for all TBTC trials;
performing data management;
managing drug supplies;
establishing site laboratory standards;
executing pharmacovigilance for TBTC trials;
presenting scientific data at conferences and in author publications; and
coordinating administrative, regulatory, and fiscal support for the TBTC.**TBTC Committees**
Several working committees make up the governance of TBTC:
The Steering Committee, made of representatives from all those engaged, makes major decisions for the group.
The Executive Affairs Group serves as the executive arm of the Steering Committee and conducts the Consortium’s day-to-day administrative business.
The Core Science Group develops the scientific program of research.
The Implementation and Quality Committee supervises the conduct and quality of ongoing studies.
The Publications and Presentations Committee assures quality and equity in TBTC’s reporting of its work.
The Advocacy and External Relations Committee represents the TBTC to outside entities, and supports the Consortium’s community engagement activities.CDC staff are represented and participate on all committees.
							
					
							Last Reviewed:  June 23, 2021						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue